Clinical Trials
3
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi
Phase 2
Recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed Tomography
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 30
- Registration Number
- NCT06466122
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Phase 2
Withdrawn
- Conditions
- Chronic Lymphocytic LeukemiaLoss of Chromosome 17p
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Kerry Rogers
- Registration Number
- NCT03943342
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Phase 1
Active, not recruiting
- Conditions
- Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Drug: Bcl-2 Inhibitor GDC-0199Biological: ObinutuzumabOther: Pharmacological StudyOther: Laboratory Biomarker AnalysisOther: Quality-of-Life Assessment
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 87
- Registration Number
- NCT02427451
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
News
No news found